SCHEMBL14814895

SCHEMBL14814895

CC(O)(c1ccncc1)c1ccc(-c2ccc(F)cc2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.46
USP2 O75604 1/20 0.46
MAPK14 Q16539 5/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
NQO2 P16083 1/20 0.36
PDE4B Q07343 3/20 0.36
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
BRAF P15056 1/20 0.35
GCGR P47871 1/20 0.35
CYP17A1 P05093 1/20 0.35
PDE4D Q08499 1/20 0.34
KIF11 P52732 1/20 0.34
SLC9A1 P19634 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
MGAM O43451 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14814647 0.80 RAB9A (0.46) RAB9AUSP2MAPK14ALDH1A1KDM4E
SCHEMBL14826094 0.78 SRC (0.32) KIF11MAPT
SCHEMBL14814684 0.77 CREBBP (0.41)
SCHEMBL11684104 0.76 USP2 (0.70) RAB9AUSP2ALDH1A1KDM4EGCGR
SCHEMBL14814468 0.75 RAB9A (0.44) RAB9AUSP2MAPK14KDM4ELMNA
SCHEMBL14814302 0.75 MAPT (0.48) RAB9AUSP2MAPK14KDM4ELMNA
SCHEMBL9205598 0.75 USP2 (0.58) RAB9AUSP2MAPK14MAPK13MAPK12
SCHEMBL14814305 0.73 RAB9A (0.49) RAB9AUSP2MAPK14ALDH1A1KDM4E
SCHEMBL14814451 0.70 USP2 (0.47) RAB9AUSP2MAPK14MAPK13MAPK12
SCHEMBL14814649 0.69 RAB9A (0.48) RAB9AUSP2LMNAMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809372-B2 Pyridine derivatives ASANA BIOSCIENCES, LLC (US) 2014-08-19 US claimed
EP-2760833-A1 PYRIDINE DERIVATIVES Endo Pharmaceuticals Inc. (US) 2014-08-06 EP claimed
US-20130085148-A1 Pyridine Derivatives ENDO PHARMACEUTICALS INC. (US) 2013-04-04 US claimed
WO-2013049559-A1 PYRIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2013-04-04 WO claimed
US-20170073339-A1 PYRIDINE DERIVATIVES ENDO PHARMACEUTICALS, INC. 2017-03-16 US disclosed
US-20170073339-A1 PYRIDINE DERIVATIVES ENDO PHARMACEUTICALS, INC. 2017-03-16 US disclosed
US-20170073339-A1 PYRIDINE DERIVATIVES ENDO PHARMACEUTICALS, INC. 2017-03-16 US disclosed
US-9533981-B2 Pyridine derivatives ASANA BIOSCIENCES, LLC (US) 2017-01-03 US disclosed
US-9533981-B2 Pyridine derivatives ASANA BIOSCIENCES, LLC (US) 2017-01-03 US disclosed
US-20160340310-A9 Pyridine Derivatives ENDO PHARMACEUTICALS, INC. 2016-11-24 US disclosed
US-20160340310-A9 Pyridine Derivatives ENDO PHARMACEUTICALS, INC. 2016-11-24 US disclosed
US-20160340310-A9 Pyridine Derivatives ENDO PHARMACEUTICALS, INC. 2016-11-24 US disclosed
US-20140235652-A1 Pyridine Derivatives ENDO PHARMACEUTICALS INC. (US) 2014-08-21 US disclosed
US-8809372-B2 Pyridine derivatives ASANA BIOSCIENCES, LLC (US) 2014-08-19 US disclosed
US-8809372-B2 Pyridine derivatives ASANA BIOSCIENCES, LLC (US) 2014-08-19 US disclosed
US-8809372-B2 Pyridine derivatives ASANA BIOSCIENCES, LLC (US) 2014-08-19 US disclosed
US-20130085148-A1 Pyridine Derivatives ENDO PHARMACEUTICALS INC. (US) 2013-04-04 US disclosed
US-20130085148-A1 Pyridine Derivatives ENDO PHARMACEUTICALS INC. (US) 2013-04-04 US disclosed
US-20130085148-A1 Pyridine Derivatives ENDO PHARMACEUTICALS INC. (US) 2013-04-04 US disclosed
WO-2013049559-A1 PYRIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085148-A1 Pyridine Derivatives CYP2A7, CYP21A2, CYP3A7 RAB9A 3164/4885USP2 1959/4885MAPK14 1449/4885
US-20170073339-A1 PYRIDINE DERIVATIVES CYP21A2, CYP26A1, CYP11B1 RAB9A 3120/4885USP2 2767/4885MAPK14 1036/4885
US-20160340310-A9 Pyridine Derivatives CYP2A7, CYP21A2, CYP3A7 RAB9A 3164/4885USP2 1959/4885MAPK14 1449/4885
US-20140235652-A1 Pyridine Derivatives CYP2A7, CYP21A2, CYP3A7 RAB9A 3164/4885USP2 1959/4885MAPK14 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.